In conclusion, the GCIG CA125 response criteria seem to overestimate a tumour response by WHO criteria when monitoring the efficacy of second-line chemotherapy with topotecan or paclitaxel–platinum in patients with epithelial ovarian carcinoma. Here, MUC16 is linked to neoplasm.